ARTICLE | Company News
Genzyme's Cerdelga gets CHMP nod for Gaucher's
November 22, 2014 2:24 AM UTC
EMA's CHMP recommended marketing authorization of Cerdelga eliglustat tartrate from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat Type I Gaucher's disease.
Cerdelga is an oral ceramide analog that inhibits glucosylceramide synthase (GCS). ...